Navigation Links
Lung Cancer Microscopic Appearance Affects Response to Chemotherapy
Date:2/17/2009

Tumor Structure Should Be Considered in Treating NSCLC, Says Report in "The Oncologist"

DURHAM, N.C., Feb. 17 /PRNewswire/ -- A tumor's cellular structure, or histology, improves treatment decisions that may lead to improved outcomes for patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, according to a paper in the latest issue of "The Oncologist."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO )

The findings are based on an analysis of recent studies of the chemotherapy drug pemetrexed to treat NSCLC. "The data confirm that histology matters when treating NSCLC," says Professor Giorgio Scagliotti, M.D., of University of Turin, lead author of the new report.

Prof. Scagliotti and colleagues analyzed data from two recent phase III studies of pemetrexed for NSCLC, which accounts for about 90 percent of all lung cancers. They focused on how differences in cancer histology affect the response to treatment with pemetrexed. The histology of a cancer is its microscopic cellular structure and in NSCLC, tumors may be classified as having a "squamous" or "non-squamous" appearance.

Their analysis showed significant differences in response to pemetrexed between these two lung cancer subtypes. Specifically, pemetrexed was more effective than current forms of chemotherapy against cancers with a non-squamous histology. For these patients, pemetrexed led to significant improvements in overall survival and in survival without progressive cancer. In contrast, for patients whose cancers had the squamous histology, outcomes were similar with or without pemetrexed.

The two studies were a "frontline" trial including patients with previously untreated NSCLC and a "second-line" trial including patients with previous chemotherapy. The interaction between cancer histology and response to pemetrexed was similar in both groups of patients. Based on the results of the frontline trial, pemetrexed has been approved for initial treatment of NSCLC in Europe, Canada and the United States, in combination with cisplatin, another chemotherapy drug.

In the past, cancer histology hasn't been considered in selecting treatments for patients with NSCLC. "For more than 25 years medical oncologists have simply looked at the distinction between small-cell and non-small-cell lung cancer in making systemic treatment decisions," says Prof. Scagliotti. "This is because there has previously been no convincing evidence that the available treatments have any differential activity based on the histologic subtype of NSCLC." "On the basis of these studies, tumor histology should be carefully assessed when selecting treatment options for patients with advanced NSCLC," says Prof. Scagliotti.

The article entitled "The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies," has been published by "The Oncologist," and is freely available online at:

http://theoncologist.com/cgi/content/abstract/theoncologist.2008-0232v1

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 27th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 14th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org

Contact: Dr. Martin J. Murphy, Executive Editor: 919.402.8750, Martin.Murphy@TheOncologist.com


'/>"/>
SOURCE AlphaMed Press
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Targeting the protein AEG1 impairs human liver cancer growth in mice
2. Hodgkins Survivors Prone to Breast Cancer Later
3. Social Disconnection in African American Women With Breast Cancer
4. Researchers ID Biomarker for Fatal Prostate Cancer
5. Teens with cancer present unique psychological issues
6. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Greece & Cyprus
7. New Anti-Clotting Treatment Urged for Cancer Patients
8. Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers
9. Normalizing tumor vessels leaves cancer more benign
10. Womens cancer outcomes improved by surgical evaluation
11. Pediatric Hodgkins disease survivors face increased breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Western University ... health services to the developmentally disabled in the Coachella Valley. , The two ... new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced ... December 31, 2015. --> --> ... revenues of $9.45 billion, up 28% on a constant ... of $9.43 billion. Excluding the impact of the acquisition ... generics business (the "EPD Business"), full year adjusted total ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, LLC, ... new approaches to the treatment of lupus and ... a multiple ascending dose study in patients with ... RSLV-132. --> --> ... multiple ascending dose study of RSLV-132 in 32 ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: